FREQ News and Press, Frequency Therapeutics Inc. From 05/10/22

Buying Penny Stocks on May 10th? Here’s What You Need to Know After another topsy turvy day of trading penny stocks and blue chips, there is a lot for investors to know. In the past few weeks, trading has been extremely difficult as a result of high inflation, rising interest rat...

Frequency Therapeutics press release (NASDAQ:FREQ): Q1 GAAP EPS of -$0.67. Cash, cash equivalents and marketable securities as of March 31, 2022, were $124.8M. These resources are sufficient to fund the ongoing Phase 2b clinical program for the Company’s lead candidate for hearing rest...

FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M, Providing Runway into 2024; Funds Enable Company to Meet Multiple Clinical Milestones for Progra...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice Pr...

3 Penny Stocks to Add to Your Late-April Watchlist If you’re looking for penny stocks to buy in April, there are a few things to keep in mind. First of all, it’s important to remember that the stock market is constantly changing, so what may be a good investment today migh...

Gainers: Casa Systems (CASA) +67%. CEL-SCI Corporation (CVM) +55%. Natus Medical (NTUS) +29%. Frequency Therapeutics (FREQ) +26%. GWG Holdings (GWGH) +20%. IMARA (IMRA) +19%. Iveda Solutions (IVDA) +18%. AgriFORCE (AGRI) +18%. Maris-Tech (MTEK) +17%. Tritium DCFC (DCFC) +12%. Losers...

Gainers: Natus Medical (NTUS) +30%. MedAvail (MDVL) +25%. IMARA (IMRA) +13%. Frequency Therapeutics (FREQ) +11%. Lyra Therapeutics (LYRA) +4%. Losers: Nektar Therapeutics (NKTR) -36%. TG Therapeutics (TGTX) -24%. Lixte Biotechnology (LIXT) -15%.&#x...

Veru (VERU) +31% after interim results for COVID-19 therapy. SailPoint Technologies (SAIL) +30% acquisition could lead to other cyber security deals, Wedbush says. Iveda Solutions (IVDA) +28%. VNET Group (VNET) +20% receives buyout offer of $1.3333 per share. Aff...

Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indication...

Frequency Therapeutics press release (NASDAQ:FREQ): Q4 GAAP EPS of -$0.62 misses by $0.98. “The year ahead has numerous milestones for Frequency and our lead program FX-322, as we plan to complete enrollment and work toward a readout of our FX-322-208 Phase 2b study of individuals with...